Luye Pharma Group Ltd. (LUP.F)

0.3500 +0.0060 (+1.74%) At close: 08:03AM CEST

Luye Pharma Group Ltd.

No. 15 Chuang Ye Road
High-tech Industrial Development Zone
Yantai 264003
China

https://www.luye.cn

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 5,270

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dian Bo Liu	Co-Founder, Executive Chairman, CEO and Head of Corporate Directions & Strategies	406.09k	N/A	1966
Mr. Rong Bing Yang	Co-Founder & Vice Executive Chairman	368.2k	N/A	1966
Mr. Hui Xian Yuan	Co-Founder & Executive Director	188.15k	N/A	1959
Ms. Yuan Yuan Zhu	Executive Director	177.62k	N/A	1981
Mr. Yuan Chong Liu	Chief Financial Officer	N/A	N/A	1964

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Corporate Governance

Luye Pharma Group Ltd.’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.